These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 19239833)

  • 1. A case report of high-dose transdermal selegiline in the treatment of major depressive disorder.
    Ashton AK
    Ann Clin Psychiatry; 2009; 21(1):51-2. PubMed ID: 19239833
    [No Abstract]   [Full Text] [Related]  

  • 2. Selegiline transdermal system: a novel treatment option for major depressive disorder.
    Nandagopal JJ; DelBello MP
    Expert Opin Pharmacother; 2009 Jul; 10(10):1665-73. PubMed ID: 19527191
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transdermal selegiline in patients receiving electroconvulsive therapy.
    Horn PJ; Reti I; Jayaram G
    Psychosomatics; 2010; 51(2):176-8. PubMed ID: 20332294
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selegiline transdermal system in major depressive disorder: profile report.
    Frampton JE; Plosker GL
    CNS Drugs; 2007; 21(6):521-4. PubMed ID: 17521230
    [No Abstract]   [Full Text] [Related]  

  • 5. Transdermal selegiline (Emsam).
    Med Lett Drugs Ther; 2006 May; 48(1235):41-2. PubMed ID: 16770292
    [No Abstract]   [Full Text] [Related]  

  • 6. Psychopharmacology column: why choose selegiline transdermal system for refractory depression?
    Tobin M
    Issues Ment Health Nurs; 2007 Feb; 28(2):223-8. PubMed ID: 17365170
    [No Abstract]   [Full Text] [Related]  

  • 7. A critical appraisal of the selegiline transdermal system for major depressive disorder.
    Bied AM; Kim J; Schwartz TL
    Expert Rev Clin Pharmacol; 2015; 8(6):673-81. PubMed ID: 26427518
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and absolute bioavailability of selegiline following treatment of healthy subjects with the selegiline transdermal system (6 mg/24 h): a comparison with oral selegiline capsules.
    Azzaro AJ; Ziemniak J; Kemper E; Campbell BJ; VanDenBerg C
    J Clin Pharmacol; 2007 Oct; 47(10):1256-67. PubMed ID: 17715422
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel transdermal delivery formulation of the monoamine oxidase inhibitor selegiline nearing release for treatment of depression.
    Thase ME
    J Clin Psychiatry; 2006 Apr; 67(4):671-2. PubMed ID: 16669733
    [No Abstract]   [Full Text] [Related]  

  • 10. Treatment-resistant depression: response to low-dose transdermal but not oral selegiline.
    Morgan PT
    J Clin Psychopharmacol; 2007 Jun; 27(3):313-4. PubMed ID: 17502787
    [No Abstract]   [Full Text] [Related]  

  • 11. The selegiline transdermal system in major depressive disorder: a systematic review of safety and tolerability.
    Robinson DS; Amsterdam JD
    J Affect Disord; 2008 Jan; 105(1-3):15-23. PubMed ID: 17568687
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transdermal selegiline: new opportunity for managing depression.
    Tobe EH
    J Am Osteopath Assoc; 2008 Feb; 108(2):85-6. PubMed ID: 18303066
    [No Abstract]   [Full Text] [Related]  

  • 13. Placing transdermal selegiline for major depressive disorder into clinical context: number needed to treat, number needed to harm, and likelihood to be helped or harmed.
    Citrome L; Goldberg JF; Portland KB
    J Affect Disord; 2013 Nov; 151(2):409-417. PubMed ID: 23890583
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Critical appraisal of selegiline transdermal system for major depressive disorder.
    Cristancho MA; Thase ME
    Expert Opin Drug Deliv; 2016; 13(5):659-65. PubMed ID: 26837935
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tyramine pressor sensitivity during treatment with the selegiline transdermal system 6 mg/24 h in healthy subjects.
    Azzaro AJ; Vandenberg CM; Blob LF; Kemper EM; Sharoky M; Oren DA; Campbell BJ
    J Clin Pharmacol; 2006 Aug; 46(8):933-44. PubMed ID: 16855078
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Commentary on the treatment effects of selegiline transdermal system on symptoms of major depressive disorder: a meta-analysis of short-term, placebo-controlled, efficacy trials.
    Carlat DJ
    Psychopharmacol Bull; 2007; 40(3):29-31. PubMed ID: 18007566
    [No Abstract]   [Full Text] [Related]  

  • 17. Use of Transdermal Selegiline in Pregnancy and Lactation: A Case Report.
    Bauer RL; Orfei J; Wichman CL
    Psychosomatics; 2017; 58(4):450-452. PubMed ID: 28501290
    [No Abstract]   [Full Text] [Related]  

  • 18. Selegiline transdermal system: current awareness and promise.
    Pae CU; Lim HK; Han C; Neena A; Lee C; Patkar AA
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Aug; 31(6):1153-63. PubMed ID: 17614182
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selegiline-transdermal--Somerset: Emsam.
    Drugs R D; 2003; 4(1):59-60. PubMed ID: 12568641
    [No Abstract]   [Full Text] [Related]  

  • 20. Leading the way: advances in the diagnosis, treatment, and management of neuropsychiatric illnesses.
    Gorman JM
    CNS Spectr; 2006 May; 11(5):338-9. PubMed ID: 16641838
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.